Upgrade to SI Premium - Free Trial

AstraZeneca (AZN) Says IMFINZI Granted Breakthrough Therapy Designation by US FDA for Patients with Locally Advanced Unresectable NSCLC

July 31, 2017 7:05 AM
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles